CINECA IRIS Institutional Research Information System

BUGIANESI, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 30.967
NA - Nord America 29.332
EU - Europa 24.446
SA - Sud America 2.161
OC - Oceania 740
AF - Africa 737
Continente sconosciuto - Info sul continente non disponibili 60
Totale 88.443
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.766
CN - Cina 19.443
IT - Italia 4.467
DE - Germania 3.249
GB - Regno Unito 2.527
JP - Giappone 2.400
FR - Francia 2.147
IN - India 2.035
ES - Italia 1.706
IE - Irlanda 1.549
SE - Svezia 1.518
KR - Corea 1.342
CA - Canada 1.280
MX - Messico 1.102
BR - Brasile 1.041
NL - Olanda 937
HK - Hong Kong 913
TR - Turchia 864
UA - Ucraina 758
TW - Taiwan 746
PL - Polonia 711
FI - Finlandia 685
AU - Australia 667
AT - Austria 588
SG - Singapore 537
GR - Grecia 528
VN - Vietnam 526
DK - Danimarca 489
RU - Federazione Russa 411
BE - Belgio 403
RO - Romania 388
EG - Egitto 364
PT - Portogallo 332
CH - Svizzera 316
IL - Israele 277
IR - Iran 277
ID - Indonesia 270
TH - Thailandia 254
PE - Perù 250
CL - Cile 244
CO - Colombia 234
AR - Argentina 208
CZ - Repubblica Ceca 177
PK - Pakistan 147
SA - Arabia Saudita 146
EC - Ecuador 123
PH - Filippine 121
MY - Malesia 119
NO - Norvegia 87
HU - Ungheria 75
ZA - Sudafrica 75
AE - Emirati Arabi Uniti 69
HR - Croazia 67
NZ - Nuova Zelanda 66
BD - Bangladesh 63
LB - Libano 53
RS - Serbia 51
LK - Sri Lanka 50
DZ - Algeria 49
BG - Bulgaria 45
EU - Europa 45
IQ - Iraq 43
LT - Lituania 42
SK - Slovacchia (Repubblica Slovacca) 38
VE - Venezuela 37
MO - Macao, regione amministrativa speciale della Cina 36
QA - Qatar 33
PA - Panama 32
MA - Marocco 31
MN - Mongolia 29
GT - Guatemala 26
KZ - Kazakistan 26
NG - Nigeria 26
TN - Tunisia 25
SI - Slovenia 23
SN - Senegal 22
JO - Giordania 21
PS - Palestinian Territory 21
CU - Cuba 20
DO - Repubblica Dominicana 20
KE - Kenya 20
MD - Moldavia 20
PR - Porto Rico 19
CR - Costa Rica 18
ET - Etiopia 18
UZ - Uzbekistan 18
BY - Bielorussia 17
CY - Cipro 17
LY - Libia 17
CM - Camerun 16
MK - Macedonia 16
IS - Islanda 15
LU - Lussemburgo 15
SV - El Salvador 15
LV - Lettonia 14
BA - Bosnia-Erzegovina 13
NI - Nicaragua 13
AP - ???statistics.table.value.countryCode.AP??? 12
KW - Kuwait 11
TZ - Tanzania 11
Totale 88.243
Salva come PNG Salva come JPEG
Città #
Beijing 3.120
Chandler 1.911
Shanghai 1.860
Dublin 1.510
Fairfield 1.505
Houston 1.366
Redwood City 1.255
Guangzhou 1.214
Ann Arbor 1.077
Nanjing 943
Ashburn 941
Wilmington 843
Woodbridge 781
Hangzhou 719
Dearborn 686
Seattle 661
Torino 611
Tokyo 576
Villeurbanne 562
Wuhan 546
Jacksonville 534
Cambridge 506
Chengdu 474
New York 460
Ottawa 444
Princeton 435
London 424
Medford 424
Taipei 416
Pisa 397
Vienna 348
Warsaw 332
Jinan 323
Duncan 321
Shenyang 315
Chongqing 312
Changsha 307
Zhengzhou 299
Nyköping 294
Boston 292
Seoul 282
Singapore 275
Dong Ket 273
Istanbul 273
Central 266
Tianjin 246
Rome 245
Milan 243
Madrid 228
Los Angeles 223
Hefei 221
Changchun 214
Turin 205
Barcelona 201
Athens 194
Fremont 190
Lima 189
Delhi 188
Fuzhou 185
San Diego 184
Santiago 179
Toronto 174
Copenhagen 164
Paris 164
Mumbai 161
Central District 158
Amsterdam 154
Sydney 143
Kunming 137
Boardman 136
Nanning 136
Nanchang 133
Xian 133
Rochester 132
São Paulo 132
Berlin 127
Washington 121
Bengaluru 120
Munich 116
Chicago 115
Hebei 115
Helsinki 114
Mexico 114
Hyderabad 112
Brussels 110
Norwalk 109
New Delhi 107
San Jose 106
Frankfurt am Main 103
Harbin 103
Shenzhen 101
Bangkok 100
Chennai 99
Kolkata 98
Mexico City 96
Phoenix 96
Jakarta 95
Philadelphia 95
Melbourne 93
Valencia 93
Totale 39.763
Salva come PNG Salva come JPEG
Nome #
Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention 17.793
Liver cancer: Connections with obesity, fatty liver, and cirrhosis 6.900
Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis 5.706
Nonalcoholic fatty liver disease 5.127
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 4.394
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 2.445
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 1.541
Advancing the global public health agenda for NAFLD: a consensus statement 1.398
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults 1.194
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 1.165
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 863
NASH in lean individuals 799
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 796
Preparing for the NASH Epidemic: A Call to Action 720
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease 660
MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease 646
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 607
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease 582
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry 582
An extended fatty liver index to predict non-alcoholic fatty liver disease. 539
From the metabolic syndrome to NAFLD or vice versa? 526
Should we undertake surveillance for HCC in patients with NAFLD? 510
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis 505
A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD 502
FibroGENE: A gene-based model for staging liver fibrosis 491
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 486
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 478
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening 469
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 456
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease 425
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 416
Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause? 370
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 354
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR 348
Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity 339
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with Nonalcoholic Fatty Liver Disease 335
Non-invasive score system for fibrosis in chronic hepatitis: Proposal for a model based on biochemical, FibroScan and ultrasound data 321
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates 307
A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease 290
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists 271
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 270
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. 267
[Non-alcoholic fatty liver disease (NAFLD)] 243
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis 235
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 234
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? 229
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis 225
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 222
Management of non-alcoholic fatty liver disease 222
Insulin resistance in nonalcoholic fatty liver disease. 218
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease 208
HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients 199
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 196
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice 193
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 186
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. 184
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 181
AISF position paper on liver disease and pregnancy. 180
Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis 180
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 178
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 178
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 173
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis 169
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 166
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 165
A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification 164
How to diagnose NAFLD in 2016 163
Hypoxia-inducible factor 2alpha drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein 163
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 157
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 155
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation 154
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 154
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 152
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study 148
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 147
Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon L-thyroxine therapy. 146
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Non-alcoholic fatty liver disease and extra-hepatic cancers 145
Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study 144
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 143
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 143
A "systems medicine" approach to the study of non-alcoholic fatty liver disease. 138
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 137
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 132
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 132
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 132
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) 129
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 129
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 126
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 125
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. 125
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 124
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 124
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 124
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 123
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 122
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 121
Metabolic handling of an oral fat load in NAFLD patients. 120
Pathophysiology of non alcoholic fatty liver disease 120
Totale 72.587
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.807
article - articoli 0
book - libri 0
conference - conferenze 26.154
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.961
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.199 0 0 0 0 0 0 0 0 0 625 1.024 550
2019/202010.744 459 500 494 976 803 1.366 995 933 1.260 1.174 995 789
2020/202115.682 895 939 959 1.162 1.702 1.373 1.438 1.020 1.622 1.597 1.411 1.564
2021/202215.717 1.019 1.156 1.209 1.480 1.336 1.173 1.365 1.324 1.547 1.115 1.509 1.484
2022/202316.573 1.266 1.141 879 1.282 1.287 2.239 1.520 1.349 1.578 1.161 1.239 1.632
2023/202417.719 1.942 1.962 1.884 2.124 2.204 2.013 1.748 2.131 706 1.005 0 0
Totale 90.696